Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Applications
- Solutions for Endometriosis
- Solutions for Severe but Non-Specific Symptoms
- Affilin - Precision Targeting Technology for Protein Drug Conjugates
- Affilin - Precision Targeting Technology for Radio Conjugates
- Affilin - Precision Targeting Technology for Cellular Therapies
- Affilin - Precision Targeting Technology for Multispecific Ligands
Drug Candidate Equipment Supplied In Europe
52 equipment items found
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
Gesynta Pharma’s drug candidate GS-073 is expected to enter clinical phase I in 2022. It is currently in the final stages of preclinical development. This project will be addressing an indication with high unmet need, which is separate from systemic ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
The drug candidate GS-659, which is sprung from Gesynta Pharma’s drug development platform, is currently in preclinical development phase. Project updates will be announced in due ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
GS-248 is Gesynta Pharma’s most advanced drug candidate, currently in clinical development as a potential treatment of systemic sclerosis. Recent clinical phase I data in healthy individuals show that GS-248 potently inhibits the production of PGE2 in a tolerable and safe manner, while increasing the observed levels of protective and vasodilatory ...
by:Oncodesign based inDijon, FRANCE
Select the best drug candidates and their biomarkers using our expertise in pharmacology! The PREDICT® technology module is a centralized manifestation of the key scientific competence of our Experimentation activity. This module is the result of more than 20 years of investment and experience that are the cornerstone of Oncodesign’s international ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our partner, Indivior, has licensed worldwide rights to our GABAB PAM program and is responsible for all development, manufacture and commercialization of any selected GABAB PAM drug candidates. Under the agreement, we are responsible for executing a research program funded by Indivior to discover novel drug candidates. Indivior ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our license agreement with Indivior provides for a funded research program, under which we have the right to select drug candidates for exclusive development in certain indications outside of SUD. We plan to develop our selected drug candidates in CMT1a, chronic cough and pain. These indications have been validated with baclofen, ...
Manufactured by:Confo Therapeutics based inGhent/Zwijnaarde, BELGIUM
Confo Therapeutics is building a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying ...
Manufactured by:Krieger AG based inMuttenz, SWITZERLAND
Dissolution of expensive shear sensitive API's, proteins, Developing and processing small molecule and complex biologic drug candidates. Or just vacuum ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
The drug candidate ABBV-0805 is a monoclonal antibody that selectively binds and eliminates oligomers and protofibrils of alpha-synuclein. The goal is to develop a disease modifying treatment that stops or slows down disease ...
Manufactured by:3B Pharmaceuticals GmbH based inBerlin, GERMANY
Discovery and preclinical development of peptide drug candidates have been 3BP’s core competencies since the company’s inception. ...
by:STALICLA based inGeneve, SWITZERLAND
DDU validates ASD phenotype groups and drug candidates through observational studies and investigational trials. DDU combines expertise in operations, medicine, drug and clinical development, to bring STALICLA’s clinical-stage treatment options closer to ...
Manufactured by:GENFIT based inLoos, FRANCE
We are conducting a research program to develop an anti-fibrotic drug candidate, with a priority given to liver fibrosis. This program consists in a repositioning of Nitazoxanide, or NTZ*, that is being investigated for the treatment of fibrosis in pre-clinical disease models. NTZ is currently being evaluated in an investigator-initiated proof-of-concept ...
Manufactured by:3B Pharmaceuticals GmbH based inBerlin, GERMANY
3B Pharmaceuticals have built a drug discovery platform extending from hit identification to early clinical development. Several drug candidates developed through our platform already have been successfully administered to humans. ...
Manufactured by:InterAx Biotech AG based inVilligen, SWITZERLAND
Our breakthrough platform combines systems biology, pharmacology, and artificial intelligence to accelerate the hit-to-lead process in GPCR drug discovery. InterAx is setting an industry example of how to better understand the biology of a disease and de-risk drug candidates. Instead of only leveraging large quantities of data with machine ...
Manufactured by:Exeliom Biosciences based inDijon, FRANCE
Our research has led us to discover that patients suffering from inflammatory bowel diseases lack a crucial bacterium and, therefore, do not have a fair chance to fight their conditions. We have developed a single bacterial strain drug candidate to deliver the key bacteria Faecalibacterium praustnizii for the treatment of inflammatory bowel diseases, starting ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
2A Pharma’s anti-amyloid-beta vaccine candidate, AAVLP-Amyloid-β, has in laboratory tests with transgenic mice over-expressing amyloid-beta mutant protein been shown to eliminate amyloid-beta soluble protein, a clear plaque from the cortex and significantly reduce plaque from the hippocampus. It is our hope that the drug candidate can ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our partnered drug candidate, ADX71149 is a novel orally active mGlu2 PAM for the treatment of epilepsy. Our partner, Janssen Pharmaceuticals, Inc., or Janssen, a subsidiary of Johnson & Johnson is conducting a placebo- controlled Phase 2a proof of concept clinical trial of ADX71149 in epilepsy patients since June 2021. ...
Manufactured by:Navigo Proteins GmbH based inHalle, GERMANY
Navigo Proteins’ Precision Targeting unit leverages its protein engineering expertise to create proprietary Affilin® molecules, harnessed to create optimized, next generation biopharmaceutical drugs in numerous fields of use. Navigo Proteins’ Affilin® platform benefits from the inherent engineerability, stability, safety, and ease of manufacturability. Our ...
Manufactured by:Bayer AG based inLeverkusen, GERMANY
However, a lot of proteins are difficult targets for SMOLs, since they do not possess defined binding sites that can be used for SMOL drug candidates and this is making them hard to drug or even “undruggable”. A new and promising approach to solve this challenge may become possible in the future. The development of new technologies ...
Manufactured by:Ncardia Services B.V. based inLeiden, NETHERLANDS
Fluorescence-based assays with iPSC-derived cardiac and neuronal models can be used to monitor short and long-term drug-induced changes on calcium transients. Our scientists develop the most optimal calcium transient assay for each project and can scale it up for high-throughput screening, to accurately evaluate efficacy and safety of drug ...